Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
2.67B | 2.69B | 2.63B | 2.59B | 2.36B | 2.12B | Gross Profit |
1.47B | 1.49B | 1.43B | 1.43B | 1.32B | 1.13B | EBIT |
655.51M | 674.00M | 672.76M | 702.36M | 615.13M | 349.55M | EBITDA |
797.34M | 810.58M | 786.74M | 771.62M | 703.55M | 446.95M | Net Income Common Stockholders |
452.36M | 467.28M | 487.49M | 513.10M | 454.37M | 249.54M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
130.42M | 115.95M | 115.68M | 163.46M | 299.97M | 208.29M | Total Assets |
5.87B | 6.00B | 5.25B | 3.82B | 3.79B | 3.67B | Total Debt |
2.30B | 2.32B | 1.86B | 737.86M | 815.90M | 1.11B | Net Debt |
2.16B | 2.20B | 1.75B | 574.40M | 515.92M | 897.70M | Total Liabilities |
2.99B | 3.07B | 2.65B | 1.53B | 1.63B | 1.92B | Stockholders Equity |
2.88B | 2.93B | 2.60B | 2.29B | 2.16B | 1.76B |
Cash Flow | Free Cash Flow | ||||
464.68M | 491.78M | 606.70M | 461.70M | 507.62M | 451.89M | Operating Cash Flow |
542.96M | 556.19M | 641.28M | 513.13M | 545.93M | 502.42M | Investing Cash Flow |
-852.95M | -844.40M | -1.44B | -222.76M | -33.17M | -194.11M | Financing Cash Flow |
307.40M | 294.50M | 750.51M | -416.01M | -422.91M | -251.53M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
82 Outperform | $11.60B | 23.45 | 19.27% | 0.88% | 6.99% | 23.25% | |
78 Outperform | $16.07B | 25.18 | 18.59% | 0.98% | -0.42% | 3.23% | |
75 Outperform | $13.57B | 28.45 | 12.73% | 1.52% | 1.66% | -17.18% | |
74 Outperform | $13.98B | 29.51 | 20.28% | 1.25% | -0.40% | -2.50% | |
71 Outperform | $11.15B | 24.94 | 16.15% | 1.54% | 0.78% | -8.42% | |
68 Neutral | $8.91B | 38.28 | 3.69% | 1.04% | -10.19% | ― | |
64 Neutral | $4.39B | 11.81 | 5.20% | 249.38% | 3.96% | -12.36% |
On April 28, 2025, Nordson Corporation announced a leadership transition in its Medical and Fluid Solutions segment, with Justin Hall promoted to Executive Vice President and segment leader, succeeding Stephen Lovass. Hall, who joined Nordson in 2006, has a strong track record and expertise in deploying the NBS Next growth framework, positioning the company for organic growth in multiple end markets. The transition aims to capitalize on market opportunities in the medical sector, which is driven by long-term growth factors such as an aging population and increasing healthcare spending.